Stock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval

Stock Track05-08

BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.

The rally was primarily driven by two key factors. First, the company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to acquire additional shares through open market transactions within three months, expressing confidence in the group's long-term prospects and growth potential. Second, the company recently received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, which further enriches its product pipeline and growth prospects.

These developments have generated positive sentiment among investors, contributing to the stock's strong performance during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160639478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160639478","market":"sg","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval","media":"Stock Track","content":"<p>BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.</p><p>The rally was primarily driven by two key factors. First, the company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to acquire additional shares through open market transactions within three months, expressing confidence in the group's long-term prospects and growth potential. Second, the company recently received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, which further enriches its product pipeline and growth prospects.</p><p>These developments have generated positive sentiment among investors, contributing to the stock's strong performance during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 6.29% in Intraday Trading on Controlling Shareholder's Share Accumulation Plan and New Product Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.</p><p>The rally was primarily driven by two key factors. First, the company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to acquire additional shares through open market transactions within three months, expressing confidence in the group's long-term prospects and growth potential. Second, the company recently received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, which further enriches its product pipeline and growth prospects.</p><p>These developments have generated positive sentiment among investors, contributing to the stock's strong performance during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1160639478","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160639478","pubTimestamp":1778205923,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.The rally was primarily driven by two key factors. First, the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"股票轨迹|控股股东股份积累计划及新产品获批宝药业-B盘中暴涨6.29%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock price surged 6.29% during intraday trading on Friday, showing significant upward momentum in the market.The rally was primarily driven by two key factors. First, the company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to acquire additional shares through open market transactions within three months, expressing confidence in the group's long-term prospects and growth potential. Second, the company recently received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, which further enriches its product pipeline and growth prospects.These developments have generated positive sentiment among investors, contributing to the stock's strong performance during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160639478","isCrawlerRequest":true}